On this page
Back to topVeradermics, Incorporated MANE
Veradermics, Incorporated listed on NYSE on 4 Feb 2026 and is not in the S&P 500. It is worth $5.2 billion. Its board has 7 directors, 6 of them independent. 5 other officers are on file. At 30 Jun 2026, Montanova Capital was its largest institutional holder, with 9.9% of the company.
- CEO
- Reid Alexander Waldman
- Listed
- 4 Feb 2026 on NYSE, IPO filings and terms
- Headquarters
- New Haven, CT
- Market cap
- $5.2B
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Board and leadership
Board and officers
Board from the proxy filed 30 Mar 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (7) | |||||
| Reid Alexander WaldmanChief Executive OfficerNot independent 路 since 2019 | |||||
| John W. ChildsDirectorIndependent 路 since 2021 路 Audit, CompensationChairman, J.W. Childs Associates, L.P.Other boards: Biohaven Ltd. | |||||
| Vlad CoricDirectorIndependent 路 since 2021 路 Compensation (chair)Chief Executive Officer, Biohaven Ltd.; Clinical Professor, Yale School of MedicineOther boards: Biohaven Ltd. and Royalty Pharma plc | |||||
| Patrick G. EnrightDirectorIndependent 路 since 2024 路 Audit (chair)Managing Director, Longitude Capital Management Co., LLCOther boards: BioAge Labs, Jazz Pharmaceuticals PLC, Vera Therapeutics and Zenas BioPharma | |||||
| David Matthew FriedmanDirectorIndependent 路 since 2025 路 Nominating and Corporate GovernanceManaging Director and Senior Analyst, Suvretta Capital Management, LLC | |||||
| Jane M. Grant-KelsDirectorIndependent 路 since 2021 路 Compensation, Nominating and Corporate Governance (chair)Vice Chair of the Department of Dermatology, Founding Director of the Cutaneous Oncology Center and Melanoma Programs and Professor of Dermatology, Pathology and Pediatrics, University of Connecticut Health Center | |||||
| Katarina PanceDirectorIndependent 路 since 2025 路 Audit, Nominating and Corporate GovernanceSenior Associate, SR One Capital Management | |||||
| Officers (5) | |||||
| Dominic Gabriel CarranoChief Financial OfficerLast filed 5 Feb 2026 | |||||
| Timothy August DursoChief Technical OfficerLast filed 18 Aug 2026 | |||||
| Michael V. GrecoGeneral CounselLast filed 5 Feb 2026 | |||||
| David HollanderChief R&D OfficerLast filed 3 Sep 2026 | |||||
| Mark NeumannChief Commercial OfficerLast filed 5 Feb 2026 | |||||
Owners and trading
Largest institutional holders
Each fund group's share of Veradermics, Incorporated. Where a company has several share classes, the share is of its total value.
13F filings for the quarter to 30 Jun 2026
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers sold $97.9 million of stock in 4 sales and bought $35.8 million in 6 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 11 Nov 2026Sale | Patrick G. EnrightDirector | $75M |
| 17 Aug 2026Sale | Reid Alexander WaldmanChief Executive Officer | $7.3M |
| 17 Aug 2026Sale | Timothy August DursoChief Technical Officer | $4.7M |
| 12 Aug 2026Sale | John W. ChildsDirector | $11M |
| 6 Feb 2026Buy | Aaron CowenDirector | $1.1M |
| 5 Feb 2026Buy | Patrick G. EnrightDirector | $18M |
| 5 Feb 2026Buy | John W. ChildsDirector | $5.0M |
| 5 Feb 2026Buy | Aaron CowenDirector | $3.7M |
| 5 Feb 2026Buy | Vlad CoricDirector | $2.0M |
| 4 Feb 2026Buy | Aaron CowenDirector | $5.8M |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
4 large insider sales in the last two years.
Insider sales of $1 million or more, and the largest tenth of Veradermics, Incorporated's insider sales.
Events, newest first
- 11 Nov 2026 Patrick G. Enright sold $75MDirector
- 17 Aug 2026 Reid Alexander Waldman sold $7.3MChief Executive Officer
- 17 Aug 2026 Timothy August Durso sold $4.7MChief Technical Officer
- 12 Aug 2026 John W. Childs sold $11MDirector
Not on file: no weekly market cap history, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.